KR102628583B1 - 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체 - Google Patents

항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체 Download PDF

Info

Publication number
KR102628583B1
KR102628583B1 KR1020227016381A KR20227016381A KR102628583B1 KR 102628583 B1 KR102628583 B1 KR 102628583B1 KR 1020227016381 A KR1020227016381 A KR 1020227016381A KR 20227016381 A KR20227016381 A KR 20227016381A KR 102628583 B1 KR102628583 B1 KR 102628583B1
Authority
KR
South Korea
Prior art keywords
alkyl
formula
compound
methyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227016381A
Other languages
English (en)
Korean (ko)
Other versions
KR20220070054A (ko
Inventor
마이클 디. 카우프만
다니엘 엘. 플린
유 미 안
락슈미나라야나 보게티
티모시 말콤 콜드웰
Original Assignee
데시페라 파마슈티칼스, 엘엘씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데시페라 파마슈티칼스, 엘엘씨. filed Critical 데시페라 파마슈티칼스, 엘엘씨.
Priority to KR1020247001621A priority Critical patent/KR20240013846A/ko
Publication of KR20220070054A publication Critical patent/KR20220070054A/ko
Application granted granted Critical
Publication of KR102628583B1 publication Critical patent/KR102628583B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
KR1020227016381A 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체 Active KR102628583B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247001621A KR20240013846A (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361792812P 2013-03-15 2013-03-15
US61/792,812 2013-03-15
KR1020217026183A KR102399891B1 (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
PCT/US2014/029661 WO2014145025A2 (en) 2013-03-15 2014-03-14 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026183A Division KR102399891B1 (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001621A Division KR20240013846A (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체

Publications (2)

Publication Number Publication Date
KR20220070054A KR20220070054A (ko) 2022-05-27
KR102628583B1 true KR102628583B1 (ko) 2024-01-25

Family

ID=51529950

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217026183A Active KR102399891B1 (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
KR1020157029134A Active KR102293086B1 (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
KR1020227016381A Active KR102628583B1 (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
KR1020247001621A Ceased KR20240013846A (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020217026183A Active KR102399891B1 (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
KR1020157029134A Active KR102293086B1 (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247001621A Ceased KR20240013846A (ko) 2013-03-15 2014-03-14 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체

Country Status (17)

Country Link
US (1) US9181223B2 (enExample)
EP (1) EP2968286B1 (enExample)
JP (6) JP6165314B2 (enExample)
KR (4) KR102399891B1 (enExample)
CN (2) CN105120864B (enExample)
AU (5) AU2014233411B2 (enExample)
BR (1) BR112015022288B1 (enExample)
CA (1) CA2903285C (enExample)
DK (1) DK2968286T3 (enExample)
ES (1) ES2651165T3 (enExample)
IL (4) IL241000B (enExample)
MX (1) MX365574B (enExample)
PH (1) PH12015502114B1 (enExample)
PT (1) PT2968286T (enExample)
RU (1) RU2015143717A (enExample)
SG (1) SG11201507660TA (enExample)
WO (1) WO2014145025A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR102399891B1 (ko) * 2013-03-15 2022-05-20 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
ES2968804T3 (es) 2017-05-24 2024-05-14 Abbisko Therapeutics Co Ltd Derivado de azaarilo, método de preparación del mismo y uso farmacéutico del mismo
WO2018233527A1 (zh) * 2017-06-19 2018-12-27 上海和誉生物医药科技有限公司 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
EP3746060A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of mastocytosis
CN110845476B (zh) * 2018-08-21 2022-11-18 上海和誉生物医药科技有限公司 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用
BR112021012812A2 (pt) * 2018-12-28 2021-12-07 Deciphera Pharmaceuticals Llc Csf1r inhibitors para uso e tratamento de câncer
CN118878519A (zh) 2019-05-10 2024-11-01 德西费拉制药有限责任公司 苯基氨基嘧啶酰胺自噬抑制剂及其使用方法
IL287795B2 (en) 2019-05-10 2025-05-01 Deciphera Pharmaceuticals Llc Heteroarylaminopyrimidine amides as autophagy inhibitors and methods of using them
WO2020257180A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
SMT202300467T1 (it) 2019-12-30 2024-01-10 Deciphera Pharmaceuticals Llc Formulazioni di inibitori di chinasi amorfi e loro procedimenti d’uso
CN118948773A (zh) 2019-12-30 2024-11-15 德西费拉制药有限责任公司 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物
EP4247795A1 (en) 2020-11-18 2023-09-27 Deciphera Pharmaceuticals, LLC Gcn2 and perk kinase inhibitors and methods of use thereof
CN115385896B (zh) * 2021-05-24 2024-11-15 上海和誉生物医药科技有限公司 一种csf-1r抑制剂中间体或其酸式盐的制备方法
CN113880812A (zh) * 2021-11-17 2022-01-04 上海皓元生物医药科技有限公司 一种csf-ir抑制剂的制备方法
MX2024007042A (es) 2021-12-09 2024-09-04 Deciphera Pharmaceuticals Llc Inhibidores de raf quinasa y metodos de uso de los mismos.
WO2023125812A1 (zh) * 2021-12-31 2023-07-06 上海海雁医药科技有限公司 取代的嘧啶酮衍生物、其药物组合物及医药上的用途
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2025122942A1 (en) * 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Solid state forms of a kinase inhibitor
WO2025122952A1 (en) * 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025231106A1 (en) * 2024-05-01 2025-11-06 Deciphera Pharmaceuticals, Llc Csf-1r inhibitors and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145023A1 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046216A1 (en) * 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
US7687522B2 (en) * 2006-12-20 2010-03-30 Amgen Inc. Substituted pyridines and pyrimidines and their use in treatment of cancer
KR20110099687A (ko) 2008-10-29 2011-09-08 데시페라 파마슈티칼스, 엘엘씨. 항-암과 항-증식성 활성을 나타내는 시클로프로판 아미드와 유사체
US9133183B2 (en) * 2013-03-15 2015-09-15 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
KR102399891B1 (ko) * 2013-03-15 2022-05-20 데시페라 파마슈티칼스, 엘엘씨. 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145023A1 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities

Also Published As

Publication number Publication date
IL241000B (en) 2018-07-31
BR112015022288A2 (pt) 2017-12-19
CN105120864B (zh) 2017-05-17
AU2018271293B2 (en) 2020-04-16
KR20210107143A (ko) 2021-08-31
SG11201507660TA (en) 2015-10-29
IL275422B (en) 2022-02-01
EP2968286A2 (en) 2016-01-20
CN107311981A (zh) 2017-11-03
AU2024202088A1 (en) 2024-05-02
IL289629B1 (en) 2023-04-01
AU2022204166B2 (en) 2024-02-15
AU2014233411A1 (en) 2015-09-17
ES2651165T3 (es) 2018-01-24
CN105120864A (zh) 2015-12-02
RU2015143717A3 (enExample) 2018-03-28
MX2015012736A (es) 2016-05-31
PT2968286T (pt) 2017-12-12
JP6165314B2 (ja) 2017-07-19
JP6936823B2 (ja) 2021-09-22
MX365574B (es) 2019-06-06
JP2016521255A (ja) 2016-07-21
IL260502B (en) 2020-07-30
DK2968286T3 (en) 2018-01-02
AU2022204166A1 (en) 2022-06-30
JP2023010738A (ja) 2023-01-20
KR20150128996A (ko) 2015-11-18
KR102293086B1 (ko) 2021-08-25
CN107311981B (zh) 2020-05-29
JP2024105360A (ja) 2024-08-06
KR102399891B1 (ko) 2022-05-20
JP2021191770A (ja) 2021-12-16
CA2903285A1 (en) 2014-09-18
AU2022204166C1 (en) 2024-06-20
IL289629A (en) 2022-03-01
JP2017193567A (ja) 2017-10-26
AU2020205294B2 (en) 2022-03-17
BR112015022288B1 (pt) 2022-06-21
AU2020205294A1 (en) 2020-08-06
IL289629B2 (en) 2023-08-01
JP2019094350A (ja) 2019-06-20
CA2903285C (en) 2021-05-11
KR20240013846A (ko) 2024-01-30
AU2014233411B2 (en) 2018-09-13
IL275422A (en) 2020-08-31
JP7169412B2 (ja) 2022-11-10
PH12015502114A1 (en) 2016-01-25
RU2015143717A (ru) 2017-04-28
WO2014145025A3 (en) 2015-01-08
AU2018271293A1 (en) 2018-12-20
JP7536064B2 (ja) 2024-08-19
EP2968286A4 (en) 2016-09-14
US9181223B2 (en) 2015-11-10
KR20220070054A (ko) 2022-05-27
EP2968286B1 (en) 2017-09-13
US20140275085A1 (en) 2014-09-18
IL241000A0 (en) 2015-11-30
PH12015502114B1 (en) 2018-06-29
WO2014145025A2 (en) 2014-09-18
HK1220398A1 (en) 2017-05-05

Similar Documents

Publication Publication Date Title
JP7536064B2 (ja) 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体
KR102386952B1 (ko) 항암 및 항-증식 활성을 나타내는 n-아실-n'-(피리딘-2-일) 우레아 및 유사체
US9133183B2 (en) Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
US9193719B2 (en) 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
HK1220398B (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301